<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">A0F60</CoID>
		<CoID Type="CompanyName">Allergan plc</CoID>
		<CoID Type="IRSNo">953872914</CoID>
		<CoID Type="CIKNo">0001578845</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="Ticker">AGN</IssueID>
			<IssueID Type="CUSIP">G0177J108</IssueID>
			<IssueID Type="ISIN">IE00BY9D5467</IssueID>
			<IssueID Type="RIC">AGN</IssueID>
			<IssueID Type="SEDOL">BY9D546</IssueID>
			<IssueID Type="DisplayRIC">AGN.N</IssueID>
			<IssueID Type="InstrumentPI">312134</IssueID>
			<IssueID Type="QuotePI">1095107</IssueID>
			<Exchange Code="NYSE" Country="USA">New York Stock Exchange</Exchange>
			<MostRecentSplit Date="1997-10-30">2.0</MostRecentSplit>
		</Issue>
		<Issue ID="2" Type="C" Desc="Common Stock" Order="2">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="InstrumentPI">149879758</IssueID>
			<Exchange Code="NYSE" Country="USA">New York Stock Exchange</Exchange>
		</Issue>
		<Issue ID="3" Type="P" Desc="Preferred Stock" Order="1">
			<IssueID Type="Name">Preference Shares</IssueID>
			<IssueID Type="InstrumentPI">190781268</IssueID>
			<Exchange Code="NA" Country="">Not Available</Exchange>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2017-08-09</LastModified>
		<LatestAvailableAnnual>2016-12-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2017-06-30</LatestAvailableInterim>
		<Employees LastUpdated="2016-12-31">16700</Employees>
		<SharesOut Date="2017-07-28" TotalFloat="333563336.0">334306189.0</SharesOut>
		<CommonShareholders Date="2016-12-31">3650</CommonShareholders>
		<ReportingCurrency Code="USD">U.S. Dollars</ReportingCurrency>
		<MostRecentExchange Date="2017-08-22">1.0</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2017-05-01T00:14:54">Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.</Text>
		<Text Type="Financial Summary" lastModified="2017-08-09T23:11:50">BRIEF: For the six months ended 30 June 2017, Allergan plc revenues increased 7% to $7.58B. Net loss applicable to common stockholders excluding extraordinary items increased from $656.5M to $3.42B. Revenues reflect US Brands segment increase of 15% to $3.2B, International Brands segment increase of 12% to $1.6B. Higher net loss reflects G/L on Invest. HFS, Maturity &amp; Trading increase from $0K to $1.98B (expense).</Text>
	</TextInfo>
	<contactInfo lastUpdated="2017-08-17T04:01:59">
		<streetAddress line="1">Clonshaugh Business And Technology Park</streetAddress>
		<streetAddress line="2">Coolock</streetAddress>
		<streetAddress line="3"></streetAddress>
		<city>DUBLIN</city>
		<state-region></state-region>
		<postalCode>D17 E400</postalCode>
		<country code="IRL">Ireland</country>
		<contactName>Karina Calzadilla</contactName>
		<contactTitle>IR Contact Officer</contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>353</countryPhoneCode>
				<city-areacode>21</city-areacode>
				<number>65235000</number>
			</phone>
			<phone type="contactphone">
				<countryPhoneCode>1</countryPhoneCode>
				<city-areacode>862</city-areacode>
				<number>2617488</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2016-03-09T08:30:05"><webSite mainCategory="Home Page">http://www.allergan.com/</webSite><eMail mainCategory="Company Contact/E-mail">investorrelations@allergan.com</eMail></webLinks>
	<peerInfo lastUpdated="2017-08-17T04:01:59">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620104010" mnem="">Pharmaceuticals - NEC</Industry>
			<Industry type="NAICS" order="1" reported="0" code="325412" mnem="">Pharmaceutical Preparation  Manufacturing</Industry>
			<Industry type="NAICS" order="2" reported="0" code="42221" mnem="">Drug, Drug Proprietaries and Druggists' Sundries Wholesalers</Industry>
			<Industry type="NAICS" order="3" reported="0" code="54171" mnem="">Research and Development in the Physical, Engineering, and Life Sciences</Industry>
			<Industry type="SIC" order="0" reported="1" code="2834" mnem="">Pharmaceutical Preparations</Industry>
			<Industry type="SIC" order="1" reported="0" code="2834" mnem="">Pharmaceutical Preparations</Industry>
			<Industry type="SIC" order="2" reported="0" code="5122" mnem="">Drugs/proprietaries/sundries</Industry>
			<Industry type="SIC" order="3" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>
		</IndustryInfo>
		<Indexconstituet>S&amp;P 500</Indexconstituet>
	</peerInfo>
	<officers>
		<officer rank="1" since="07/01/2014">
			<firstName>Brenton</firstName>
			<mI>L.</mI>
			<lastName>Saunders</lastName>
			<age>47 </age>
			<title startYear="2016" startMonth="10" startDay="26" iD1="CHM" abbr1="Chmn." iD2="PRE" abbr2="Pres.">Chairman of the Board, President, Chief Executive Officer</title>
		</officer>
		<officer rank="2" since="12/08/2014">
			<firstName>Maria</firstName>
			<mI>Teresa Bernas</mI>
			<lastName>Hilado</lastName>
			<age>52 </age>
			<title startYear="2016" startMonth="" startDay="" iD1="CFO" abbr1="CFO" iD2="" abbr2="">Chief Financial Officer</title>
		</officer>
		<officer rank="3" since="11/16/2009">
			<firstName>Robert</firstName>
			<mI>A.</mI>
			<lastName>Stewart</lastName>
			<age>49 </age>
			<title startYear="2016" startMonth="05" startDay="" iD1="COO" abbr1="COO" iD2="" abbr2="">Chief Operating Officer</title>
		</officer>
		<officer rank="4" since="07/2014">
			<firstName>Karen</firstName>
			<mI>Lee</mI>
			<lastName>Ling</lastName>
			<age>53 </age>
			<title startYear="2016" startMonth="" startDay="" iD1="CHO" abbr1="Chief HR" iD2="" abbr2="">Chief Human Resource Officer</title>
		</officer>
		<officer rank="5" since="08/07/2013">
			<firstName>James</firstName>
			<mI>C.</mI>
			<lastName>D'Arecca</lastName>
			<age>46 </age>
			<title startYear="2013" startMonth="08" startDay="07" iD1="CAO" abbr1="CAO" iD2="" abbr2="">Chief Accounting Officer</title>
		</officer>
		<officer rank="6" since="07/2014">
			<firstName>William</firstName>
			<mI>J.</mI>
			<lastName>Meury</lastName>
			<age>49 </age>
			<title startYear="2016" startMonth="05" startDay="" iD1="OTH" abbr1="Other" iD2="" abbr2="">Chief Commercial Officer</title>
		</officer>
		<officer rank="7" since="03/2015">
			<firstName>C.</firstName>
			<mI>David</mI>
			<lastName>Nicholson</lastName>
			<age>62 </age>
			<title startYear="2015" startMonth="03" startDay="" iD1="OTH" abbr1="Other" iD2="" abbr2="">Chief R&amp;D Officer</title>
		</officer>
		<officer rank="8" since="07/2014">
			<firstName>A. Robert</firstName>
			<mI>D.</mI>
			<lastName>Bailey</lastName>
			<age>53 </age>
			<title startYear="2016" startMonth="" startDay="" iD1="SEC" abbr1="Secy." iD2="" abbr2="">Chief Legal Officer and Corporate Secretary</title>
		</officer>
	</officers>
	<Ratios PriceCurrency="USD" ReportingCurrency="USD" ExchangeRate="1.00000" LatestAvailableDate="2017-06-30">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">222.27000</Ratio>
			<Ratio FieldName="NHIG" Type="N">256.80000</Ratio>
			<Ratio FieldName="NLOW" Type="N">184.50000</Ratio>
			<Ratio FieldName="PDATE" Type="D">2017-08-23T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">2.18536</Ratio>
			<Ratio FieldName="EV" Type="N">103648.33000</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">74306.23000</Ratio>
			<Ratio FieldName="TTMREV" Type="N">15066.80000</Ratio>
			<Ratio FieldName="TTMEBITD" Type="N">3972.50000</Ratio>
			<Ratio FieldName="TTMNIAC" Type="N">-3981.80000</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="TTMEPSXCLX" Type="N">-11.66421</Ratio>
			<Ratio FieldName="TTMREVPS" Type="N">42.45963</Ratio>
			<Ratio FieldName="QBVPS" Type="N">225.14340</Ratio>
			<Ratio FieldName="QCSHPS" Type="N">17.43759</Ratio>
			<Ratio FieldName="TTMCFSHR" Type="N">8.24686</Ratio>
			<Ratio FieldName="TTMDIVSHR" Type="N">1.40000</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="TTMGROSMGN" Type="N">87.10741</Ratio>
			<Ratio FieldName="TTMROEPCT" Type="N">-5.60798</Ratio>
			<Ratio FieldName="TTMPR2REV" Type="N">4.93179</Ratio>
			<Ratio FieldName="PEEXCLXOR" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="PRICE2BK" Type="N">1.05648</Ratio>
			<Ratio FieldName="Employees" Type="N">16700</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="Mean" CurFiscalYear="2017" CurFiscalYearEndMonth="12" CurInterimEndCalYear="2017" CurInterimEndMonth="9" EarningsBasis="PRX">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">2</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">266.12500</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">13.2508</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">13.65958</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">15923.69580</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">4042.48800</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">16.27210</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">4.18600</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">5791.64630</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">2.93830</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
